Advertisement

Leprosy pp 43-47 | Cite as

Classification

  • Cesare Massone
  • Alexandra M. G. Brunasso
Chapter

Abstract

Diagnosis and classification are two essential points for correct patient management. Correct classification allows proper treatment and alerts of the risk of leprosy reaction and nerve damage. The Ridley–Jopling classification recognizes the complex pathogenesis of leprosy and is based on a spectrum that extends from tuberculoid leprosy (TT), through borderline tuberculoid (BT), mid-borderline (BB), borderline lepromatous (BL), to the poorly resistant lepromatous leprosy (LL). The World Health Organization (WHO) classification, for therapeutic purposes, divides patients into paucibacillary (PB) and multibacillary (MB) on the basis of the number of skin lesions. PB cases have up to five skin lesions in total, whereas MB cases have six or more skin lesions. The two systems are complementary rather than exclusive.

Keywords

World Health Organization Skin Lesion Lepromatous Leprosy Complex Pathogenesis Epithelioid Granuloma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ridley DS (1988) Pathogenesis of leprosy and related diseases. Wright, London, Boston, Singapore, Sydney, Toronto, WellingtonGoogle Scholar
  2. 2.
    Ridley DS, Jopling WH (1962) A classification of leprosy for research purposes. Lepr Rev 33:119–128PubMedGoogle Scholar
  3. 3.
    Ridley DS, Jopling WH (1966) Classification of leprosy according to immunity—a five-group system. Int J Lepr Other Mycobact Dis 34:255–273PubMedGoogle Scholar
  4. 4.
    Ridley DS (1988) Nature of the leprosy spectrum. In: Ridley DS (ed) Pathogenesis of leprosy and related diseases. Wright, London, Boston, Singapore, Sydney, Toronto, Wellington, pp 93–105Google Scholar
  5. 5.
    Noto S, Clapasson A, Nunzi E (2007) Classification of leprosy: the mistery of “reactional tuberculoid”. G Ital Dermatol Venereal 142:294–295Google Scholar
  6. 6.
    WHO (1982) Chemotherapy of leprosy for control programmes. Technical report series 675. World Health Organization, GenevaGoogle Scholar
  7. 7.
    WHO (1988) A guide to leprosy control, 2nd edn. GenevaGoogle Scholar
  8. 8.
    WHO (2009) Enhanced global strategy for further reducing the disease burden due to leprosy (2011–2015). Operational Guidelines (Updated)Google Scholar
  9. 9.
    Guia para o controle da hanseniase (2002) Brasilia DF Ministério da Saúde. http://bvsms.saude.gov.br/bvs/publicacoes/guia_de_hanseniase.pdf
  10. 10.
    Talhari S (1996) Diagnosis, classification and prognosis. Int J Lepr 64(suppl):s13–s14Google Scholar
  11. 11.
    Parkash O (2009) Classification of leprosy into multibacillary and paucibacillary groups: an analysis. FEMS Immunol Med Microbiol 55:1–5PubMedCrossRefGoogle Scholar
  12. 12.
    Buhrer-Sekula S, Visschedijk J, Grossi MAF et al (2007) The ML Flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients. Lepr Rev 78:271–279Google Scholar
  13. 13.
    Lockwood DN, Sarno E, Smith WC (2007) Classifying leprosy patients–searching for the perfect solution? Lepr Rev 78:317–320PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  1. 1.Department of DermatologyMedical University of GrazGrazAustria

Personalised recommendations